CapsoVision expects AI-assisted reading clearance around midyear, with CapsoCam Colon Gen 2 imaging and AI module targeted for Q3 2026
View original at seekingalpha.com“We ended the quarter with $17.9 million in cash and cash equivalents”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Tariffs impacting cost of goods sold were the primary driver of gross margin decline from 54% to 48% year-over-year
60% confidenceColon study investment will continue through Q3 2026 and OpEx will only begin to trail off in Q4 2026
60% confidenceCapsoVision shipped 6,229 CapsoCam Plus capsules in Q1 2026 versus 6,447 in Q1 2025, a 3% year-over-year decrease reflecting timing of shipments moved into Q2
60% confidenceCapsoCam Colon Gen 2 development program remains on track with imaging of the second-generation capsule and AI module expected in Q3 2026
60% confidenceThe modest decrease in capsule volume was offset by a slight increase in average selling price
60% confidenceCapsoVision secured key renewals for large GI networks including Indiana University Health Systems, Providence Health Systems and Gastro Health during Q1 2026
60% confidenceIncreased OpEx driven by development work for next-generation imaging sensor under Canon agreement and CapsoCam Colon Gen 2 clinical trial activities
60% confidenceThe underlying business remains strong
60% confidenceUnderlying procedure volume reflecting end user consumption continued to expand
60% confidenceEnrollment began in the clinical study for the CapsoCam UGI/pancreatic initiative
60% confidenceRevenue and new account additions remained stable year-over-year while CapsoCams were expanded to detect a widening range of mobile diseases
60% confidence